{"url_path":"/sec/sgmt/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001193125-26-343446-index.html","accession_number":"0001193125-26-343446","cik":"0001400118","ticker":"SGMT","issuer_name":"Sagimet Biosciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001193125-26-343446-index.html","primary_entity_key":"0001400118","primary_entity_name":"Sagimet Biosciences Inc."},"word_count":94,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\nNo.\n\n  \n\nDocument\n\n99.1\n  \n[Press Release of Sagimet Biosciences Inc., dated August 11, 2026.](d36435dex991.htm)\n\n99.2\n  \n[Investor Presentation of Sagimet Biosciences Inc., dated August 11, 2026.](d36435dex992.htm)\n\n104\n  \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nSagimet Biosciences Inc.\n\nDate: August 11, 2026\n\n \n\n \nBy:\n \n\n/s/ David Happel\n\n \n\n \n\n \nDavid Happel\n\n \n\n \n\n \nChief Executive Officer"}